Table 1– Subject characteristics
Not using inhaled GCUsing inhaled GC
Subjects n3950
Females19 (48)25 (50)
Age years50 (24–70)51 (22–71)
Atopy26 (68)36 (75)
Current smokers17 (43)9 (18)*
Smoking exposure pack-years8.4 (0–47.3)0.2 (0–63.8)
Pre-BD FEV1 L2.9 (1.6–5.9)2.7 (1.4–4.5)
Pre-BD FEV1 % pred90.3 (53.9–113.7)86.3 (51.6–128.7)
Pre-BD FEV1/VC %69.6 (45.8–89.5)66.5 (40.3–94.4)
Pre-BD PEF L·s−17.2 (4.7–14.9)7.9 (4.0–14.2)
Pre-BD MEF50 L·s−12.4 (1.0–5.6)2.3 (0.6–5.3)
Reversibility % pred10.0 (-2.2–33.2)9.5 (1.5–38.4)
AMP PC20 mg·mL−178.7 (0.02–>640)51.5 (0.01–>640)
Total IgE IU·L−145 (0–604)2 (0–1668)
Blood eosinophils ×109 per L0.20 (0.01–0.51)0.20 (0.06–1.16)
Sputum eosinophils %1.2 (0–7.3)0.8 (0–65.8)
Sputum neutrophils %53.0 (11.8–87.7)54.0 (15.3–90.0)
Alveolar NO ppb5.57 (2.13–18.34)5.63 (1.49–51.72)
Bronchial NO nL·s−10.64 (0.06–3.17)0.89 (0.20–10.38)
Control according to GOAL criteria24 (72)24 (51)
  • Data are presented as n (%) or median (range), unless otherwise stated. GC: glucocorticoid; BD: bronchodilator; FEV1: forced expiratory volume in 1 s; VC: vital capacity; PEF: peak expiratory flow; MEF50: half-maximal expiratory flow; AMP: adenosine monophosphate; PC20: provocative concentration causing a 20% fall in FEV1; GOAL: Gaining Optimal Asthma Control. *: p≤0.05 versus not using inhaled GC.